By Fineline Cube Ocumension Therapeutics (HKG: 1477) announced that China’s National Medical Products Administration (NMPA) has approved the new drug application for OT-502 (DEXYCU, Shishu), a single-dose, sustained-release dexamethasone intraocular suspension indicated for the treatment of postoperative ocular inflammation. This approval marks a significant milestone as OT-502 becomes available to Chinese patients following its prior FDA approval in the United States.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | New Drug Application Approval |
| Product | OT-502 (DEXYCU, Shishu) – dexamethasone intraocular suspension |
| Indication | Treatment of postoperative ocular inflammation |
| Approval Date | 2 July 2026 |
| Global Status | Previously approved by US FDA as first and only single-dose sustained-release intraocular steroid for this indication |
Drug Profile & Innovation
- Molecule: Dexamethasone intraocular suspension (corticosteroid)
- Delivery System: Single-dose, sustained-release formulation administered directly into the eye during surgery
- Innovation: First and only single-dose, sustained-release intraocular steroid approved by FDA for postoperative inflammation
- Clinical Validation: Phase III trial in post-cataract surgery inflammation achieved primary endpoints in 2024
- Therapeutic Advantage: Eliminates need for multiple postoperative topical steroid drops, improving patient compliance and reducing treatment burden
Clinical Evidence – Phase III Trial
| Endpoint | Result | Significance |
|---|---|---|
| Primary Endpoint Achievement | Met in 2024 | Statistically significant reduction in postoperative inflammation |
| Patient Population | Post-cataract surgery patients | Largest segment requiring postoperative anti-inflammatory treatment |
| Treatment Paradigm | Single intraoperative administration | Replaces 2–4 weeks of multiple daily topical steroid drops |
| Safety Profile | Consistent with dexamethasone class | No new safety signals identified in pivotal trial |
Market Impact & Strategic Positioning
| Aspect | Details |
|---|---|
| China Ophthalmology Market | Estimated 4+ million cataract surgeries annually, growing at 8% CAGR |
| Current Standard of Care | Multiple daily topical steroid drops for 2–4 weeks post-surgery |
| Competitive Landscape | No other single-dose sustained-release intraocular steroids approved in China |
| Commercial Advantage | Seamless integration into existing cataract surgery workflow |
| Revenue Potential | Significant market opportunity given high procedure volume and unmet need for simplified postoperative care |
Forward Outlook
The NMPA approval positions Ocumension Therapeutics to address a substantial unmet need in China’s rapidly growing ophthalmic surgery market. With OT-502’s proven clinical efficacy and convenient single-dose administration, the company expects strong adoption among ophthalmologists seeking to improve patient outcomes while simplifying postoperative management.
Ocumension plans to leverage its established commercial infrastructure and relationships with key opinion leaders in Chinese ophthalmology to drive rapid market penetration. The approval also strengthens Ocumension’s portfolio of innovative ophthalmic therapeutics and reinforces its position as a leader in bringing globally validated treatments to the Chinese market.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical outcomes, and commercial expectations for OT-502. Actual results may differ due to risks including market adoption rates, competitive dynamics, and reimbursement considerations.-Fineline Info & Tech